REVIEW article

Front. Immunol., 20 October 2025

Sec. Inflammation

Volume 16 - 2025 | https://doi.org/10.3389/fimmu.2025.1677808

Exosome-based modulation of ferroptosis in neurological disorders: mechanisms, therapeutic potential, and translational challenges

  • XB

    Xiaoying Bao 1†

  • LC

    Liwei Chen 1†

  • HY

    Hong Yu 1†

  • YX

    Yunan Xie 2

  • LL

    Liangxiao Luo 1

  • LL

    Li Luo 3

  • HW

    Hanbing Wang 4

  • RC

    Rongbing Chen 5

  • YC

    Yongwei Cheng 6

  • DS

    Da Sun 7*

  • CZ

    Chunwu Zhang 1*

  • 1. Geriatrics Center, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China

  • 2. Cixi Biomedical Research Institute, Wenzhou Medical University, Cixi, China

  • 3. Department of Critical Care Medicine, Yiwu Central Hospital, the Affiliated Yiwu Hospital of Wenzhou Medical University, Yiwu, China

  • 4. Department of Biotechnology, The University of Hong Kong, Kowloon, Hong Kong SAR, China

  • 5. Department of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, China

  • 6. National Engineering Research Center of Cell Growth Factor Drugs and Protein Biologics, Wenzhou Medical University, Wenzhou, China

  • 7. Institute of Life Sciences & Biomedical Collaborative Innovation Center of Zhejiang Province, Wenzhou University, Wenzhou, China

Abstract

Neurological disorders, including acute insults such as stroke and traumatic brain injury and chronic neurodegenerative diseases like Alzheimer’s disease and Parkinson’s disease, exert a profound global health burden. Ferroptosis, a distinct form of regulated cell death driven by iron accumulation, lipid peroxidation, and oxidative stress, has emerged as a central pathological mechanism across these conditions. Exosomes, nanoscale extracellular vesicles capable of crossing the blood-brain barrier and delivering functional cargos such as microRNAs, long non-coding RNAs, and proteins, have demonstrated remarkable potential in modulating ferroptotic signaling. Through regulation of the GPX4–GSH axis, ferritinophagy, iron homeostasis, and antioxidant pathways, exosome-based interventions offer neuroprotective benefits in diverse models of neurological injury. This review synthesizes current advances in the mechanistic understanding of ferroptosis and highlights emerging strategies leveraging exosomes as precision delivery platforms for ferroptosis-targeted therapy. We also discuss the translational challenges and future directions necessary to realize exosome-guided neuroprotection as a viable clinical paradigm.

1 Introduction

Neurological disorders, encompassing both acute brain injuries such as ischemic stroke and traumatic brain injury (TBI), and chronic neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), represent a mounting global health crisis (). These conditions collectively account for a substantial proportion of mortality and long-term disability worldwide, global DALY counts attributed to these conditions increased by 18.2% (8.7–26.7) between 1990 and 2021, as reported in the Global Burden of Disease Study 2021 (). Despite their clinical heterogeneity, they share convergent pathophysiological mechanisms, most notably, oxidative stress, neuroinflammation, and iron dysregulation, which synergistically drive progressive neural cell damage and functional decline ().

The scale of the global burden is striking. Data from the World Stroke Organization and GBD 2021 indicate that stroke affects 93.8 million people globally, with approximately 11.9 million new cases and 7.3 million deaths (10.7% of all deaths) reported in 2021 alone (). The World Health Organization estimates that TBI, often resulting from falls, vehicular accidents, or sports-related trauma, accounts for an estimated 50–60 million new cases each year and incurs a global economic burden of over $400 billion (). Meanwhile, Alzheimer’s Disease International (ADI) reports that neurodegenerative diseases such as AD and PD afflict over 50 million people globally, a number projected to surpass 139 million by 2050 due to population aging (). With the aging of the world’s population, age-related neurodegenerative diseases have become one of the biggest problems to be solved urgently in modern society (). These conditions are not only devastating to individuals and families but also place extraordinary strain on healthcare systems.

Emerging evidence implicates ferroptosis as a common and critical form of regulated cell death underlying diverse neurological disorders. Ferroptosis is an iron-dependent, non-apoptotic cell death modality characterized by overwhelming lipid peroxidation and reactive oxygen species (ROS) accumulation. Central to this process is the dysregulation of intracellular iron metabolism and the depletion of key antioxidant systems, particularly glutathione (GSH) and its associated enzyme GSH peroxidase 4 (GPX4) (). In acute neurological insults such as ischemic stroke and TBI, ferroptosis is initiated by iron overload and ROS generation through Fenton chemistry, leading to neuronal injury and secondary damage (, ). Ferroptosis plays a pivotal role in the pathogenesis of neurodegenerative diseases, and targeting key regulatory genes involved in this process can effectively delay neurodegeneration (, ).

Given its pivotal role in neuronal vulnerability, ferroptosis has emerged as an attractive target for therapeutic intervention across a spectrum of neurological conditions. Among the innovative strategies under investigation, exosomes, a subtype of extracellular vesicles (40–160 nm) secreted by various cell types, have garnered increasing attention as both biomarkers and delivery vehicles for therapeutic agents (, ). Exosomes carry a cargo of bioactive molecules, including proteins, lipids, and nucleic acids (eg., mRNAs, microRNAs (miRNAs), long non-coding RNAs, DNA, etc.), which they transfer between cells to regulate intercellular communication and modulate recipient cell function (, ). Their ability to cross physiological barriers such as the blood-brain barrier (BBB), evade immune detection, and deliver functional cargo to specific cell types renders them highly promising candidates for neurotherapeutics (, ). Importantly, emerging research suggests that exosomes may exert direct neuroprotective effects by modulating ferroptosis-related pathways (). Through targeted delivery of antioxidant molecules, iron regulators, and gene-modifying RNAs, exosomes can suppress oxidative stress, restore redox balance, and inhibit ferroptosis-driven neural damage. Compared to synthetic nanocarriers, exosomes offer superior biocompatibility, reduced toxicity, and intrinsic targeting potential, making them a versatile platform for developing next-generation therapies for neurological disorders (Figure 1).

Figure 1

Nevertheless, despite the substantial burden of neurological disorders and growing evidence for ferroptosis as a convergent pathological mechanism, the therapeutic potential of exosome-based ferroptosis modulation remains underexplored. Few studies provide systematic comparisons across exosome sources or disease contexts, and clinical validation is still lacking. Addressing these knowledge gaps provides the rationale for this review.

This review aims to systematically elucidate the mechanistic interplay between exosome biology and ferroptosis regulation in neurological diseases. We first dissect the molecular underpinnings of ferroptosis and its contribution to acute and chronic neurodegeneration. We then explore how exosome-mediated delivery of therapeutic cargos—particularly regulatory RNAs and antioxidant proteins—modulates ferroptotic signaling cascades. Finally, we discuss the challenges and innovations in exosome engineering for Central nervous system(CNS)-targeted therapy, offering perspectives on the clinical translation of exosome-based interventions for ferroptosis-driven neurological injury.

2 The molecular mechanisms of ferroptosis and its pathological role in neurological disorders

2.1 Molecular mechanisms underlying ferroptosis

Ferroptosis is a distinct, iron-dependent form of regulated cell death characterized by the accumulation of lethal lipid peroxides and uncontrolled oxidative stress (). Unlike apoptosis, necrosis, and autophagy, ferroptosis is fundamentally driven by iron-mediated redox imbalance and extensive lipid membrane damage, and it has been recognized as a central mechanism underlying the progression of various neurological disorders (, , ). At the molecular level, ferroptosis is primarily orchestrated by three interconnected pathways: iron metabolism, lipid peroxidation, and the cellular antioxidant defense system.

2.1.1 Dysregulation of iron homeostasis

Iron plays a critical role in numerous physiological processes, including DNA synthesis, oxygen transport, and mitochondrial energy metabolism. Physiologically, ferric iron (Fe³+) circulates in a redox-inactive form bound to transferrin, whereas ferrous iron (Fe²+) is highly reactive and soluble (). When cellular iron regulation is impaired, excess Fe²+ catalyzes the Fenton reaction, producing hydroxyl radicals (·OH) that inflict widespread oxidative damage ().

Key regulators of systemic and cellular iron homeostasis include hepcidin, which inhibits intestinal iron absorption by promoting the degradation of the iron exporter ferroportin (FPN), and hypoxia-inducible factors (HIFs), which suppress hepcidin under hypoxic conditions, thereby enhancing iron mobilization (, ). Overload of labile iron leads to the generation of toxic non-transferrin-bound iron (NTBI), promoting ROS formation and initiating lipid peroxidation cascades (, ). Intracellularly, iron is safely sequestered within ferritin complexes. Under pathological conditions, ferritin is degraded via autophagic pathways mediated by nuclear receptor coactivator 4 (NCOA4), a process termed ferritinophagy, liberating iron into the labile pool and exacerbating oxidative stress ().

2.1.2 Induction of lipid peroxidation

The hallmark of ferroptosis is the iron-catalyzed peroxidation of polyunsaturated fatty acids (PUFAs) incorporated into phospholipids of cellular membranes. Critical enzymes such as acyl-CoA synthetase long-chain family member 4 (ACSL4) and lysophosphatidylcholine acyltransferase 3 (LPCAT3) facilitate the esterification and remodeling of PUFAs into membrane phospholipids, rendering them susceptible to oxidative damage ().

Upon ROS attack, PUFAs are converted into lipid hydroperoxides (PUFA-OOH) (, ). If not adequately detoxified, these peroxides disrupt membrane integrity, cause bioenergetic failure, and trigger ferroptotic cell death. In contrast, monounsaturated fatty acids (MUFAs) can attenuate lipid peroxidation by competing with PUFAs for incorporation into membranes, a process involving ACSL3 activity, thus serving as a protective mechanism against ferroptosis (, ).

2.1.3 Failure of antioxidant defense systems

The redox homeostasis of the cell is crucial for preventing ferroptosis. Central to this defense is GSH, the most abundant cellular antioxidant, and its associated enzyme GPX4. GPX4 catalyzes the reduction of phospholipid hydroperoxides into non-toxic phospholipid alcohols, preserving membrane integrity ().

The system Xc- transporter, composed of Solute carrier family 7 member 11(SLC7A11) and Solute carrier family 3, member 2(SLC3A2) subunits, imports cystine in exchange for glutamate, thereby sustaining intracellular cysteine levels essential for GSH synthesis. Disruption of system Xc- activity, whether by extracellular glutamate accumulation or pharmacological inhibition, depletes GSH, reduces GPX4 activity, and sensitizes cells to ferroptosis ().

Mitochondrial redox balance also plays a critical role, with solute carrier proteins such as Solute carrier family 25 member 11(SLC25A11) and Solute carrier family 25 member 10(SLC25A10) mediating GSH transport across mitochondrial membranes. Loss of mitochondrial antioxidant capacity exacerbates ferroptotic stress (). Notably, direct inhibition of GPX4, either through genetic deletion or chemical inhibitors, rapidly triggers ferroptosis, highlighting its indispensable role in maintaining neuronal survival under oxidative conditions.

2.1.4 GPX4-independent ferroptosis suppressor pathways

In addition to the canonical GPX4–GSH system, several parallel pathways have been identified that independently suppress ferroptosis. Ferroptosis suppressor protein 1 (FSP1), a flavoprotein localized to the plasma membrane, catalyzes the NAD(P)H-dependent reduction of Coenzyme Q10(CoQ10) to Coenzyme Q H2(CoQH2), thereby halting lipid peroxidation chain reactions; it can also reduce vitamin K, providing an additional antioxidant defense (, ). Structural and pharmacological studies further revealed that FSP1 functions as a dimeric flavoprotein generating 6-hydroxy-FAD with intrinsic anti-ferroptotic activity, while small-molecule inhibitors such as iFSP1 competitively target its NAD(P)H-binding site (, ). A second ferroptosis defense pathway involves dihydroorotate dehydrogenase (DHODH), a mitochondrial inner membrane enzyme primarily recognized for its role in pyrimidine biosynthesis. Beyond this metabolic function, DHODH reduces CoQ10 within mitochondria, maintaining redox homeostasis and preventing lipid peroxidation–induced ferroptosis (). Together, FSP1 and DHODH complement GPX4 to form a multilayered protective network that safeguards cellular and mitochondrial integrity under oxidative stress.

2.2 The pathological role of ferroptosis in neurological disorders

Accumulating evidence implicates ferroptosis as a pivotal pathological mechanism across a spectrum of neurological diseases, including stroke, TBI, AD, and PD. The contribution of ferroptosis to neural injury can be attributed to three major interrelated processes: oxidative stress amplification, membrane lipid peroxidation, and iron-dependent neuronal death.

2.2.1 Oxidative stress and iron-driven neurotoxicity

In acute brain injuries such as ischemic and hemorrhagic stroke, as well as TBI, BBB disruption and hemorrhage result in excessive iron deposition in the parenchyma. This iron catalyzes ROS production via Fenton chemistry, causing oxidative damage to proteins, nucleic acids, and lipids, and ultimately impairing neuronal function and viability ().

In AD models, ferroptosis-related molecular alterations have been demonstrated (Figure 2). Representative evidence shows that restoring antioxidant enzymes (e.g., GPX4, xCT, FSP1), modulating ferritinophagy (via NCOA4–FTH1 axis), and improving redox balance collectively mitigate ferroptotic injury and may enhance neuronal viability in AD.

Figure 2

). (B) Tetrahedral framework nucleic acids increased cell viability and GSH levels while reducing Fe²+, MDA, LDH, and lipid peroxidation in Aβ-treated N2a cells. Reproduced from Tan et al., 2024, Nanobiotechnology, with permission (). (C) Tau K677R mutation alleviated ferroptosis by regulating NCOA4-dependent ferritinophagy and upregulating FTH1 expression, thereby maintaining iron homeostasis and neuronal viability. Reproduced from An et al., 2024, Free Radical Biology and Medicine, with permission (). APP/PS1, amyloid precursor protein/presenilin-1; WT, wild type; CLNDSe, core–liposome–nanodots selenium nanoparticle; ACSL4, acyl-CoA synthetase long-chain family member 4; GPX4, glutathione peroxidase 4; FTH1, ferritin heavy chain 1; COX2, cyclooxygenase-2; DAPI, 4′,6-diamidino-2-phenylindole; Cy5, cyanine 5; TFNA, tetrahedral framework nucleic acid; NRF2, nuclear factor erythroid 2–related factor 2; FSP1, ferroptosis suppressor protein 1; SLC7A11/xCT, cystine/glutamate antiporter; NCOA4, nuclear receptor coactivator 4; Tau K677R, Tau K677R mutation; β-ACTIN, beta-actin.

Beyond AD, similar dysregulation of iron homeostasis has been observed in other chronic neurodegenerative diseases such as PD, leading to pathological iron accumulation in vulnerable brain regions (e.g., substantia nigra, hippocampus) (, ). A recent review also highlights that oxidative stress, immunological dysfunction, and microbiota shifts collectively shape the pathogenesis of ferroptosis-related neurodegeneration (). Such elevation of labile iron pools perpetuates oxidative stress, thereby exacerbating synaptic dysfunction and neuronal death.

2.2.2 Lipid peroxidation and membrane disruption

A defining feature of ferroptosis-mediated neural injury is extensive lipid peroxidation. ROS-induced oxidation of PUFA-containing phospholipids compromises membrane fluidity and integrity, resulting in increased membrane permeability, cytoplasmic leakage, and organelle dysfunction. Lipid peroxidation products, such as malondialdehyde (MDA) and 4-hydroxynonenal (4-HNE), further amplify cellular injury by forming cytotoxic adducts with proteins and DNA, thereby propagating neurodegeneration ().

2.2.3 Neuronal ferroptotic death and functional impairment

Loss of GPX4 activity and GSH depletion render neurons exceptionally vulnerable to ferroptosis. Reduced capacity to detoxify lipid peroxides leads to the activation of ferroptotic death pathways, contributing to neuronal loss and functional deterioration in both acute injuries and chronic neurodegenerative conditions ().

Preclinical studies have demonstrated that pharmacological inhibition of ferroptosis, using agents such as ferrostatin-1 and liproxstatin-1, or enhancement of antioxidant defenses through N-acetylcysteine supplementation, can significantly reduce infarct volume, improve neurological outcomes, and protect against cognitive decline in various models of stroke, TBI, and neurodegeneration ().

These findings underscore the critical role of ferroptosis as a unifying mechanism driving neuronal damage and identify it as a promising therapeutic target for the treatment of neurological disorders.

As shown in Figure 3, ferroptosis-associated oxidative stress has been implicated in TBI, contributing to secondary neuronal damage. High-altitude hypoxia further aggravates ferroptosis by upregulating Bach1, increasing ROS levels, and reducing Ferritin heavy chain 1 (FTH1) expression, thereby weakening antioxidant defenses. Conversely, NRF2 activation via DMF treatment restores the xCT–GPX4 axis and enhances FSP1–ferritin–mediated iron sequestration, ultimately maintaining redox homeostasis. These findings underscore that ferroptosis in TBI is dynamically regulated by the balance between pro-oxidant (Bach1-driven) and antioxidant (NRF2-dependent) signaling.

Figure 3

). (B) NRF2 activation alleviates TBI-induced ferroptosis by restoring the xCT–GPX4 antioxidant system, enhancing ferritin (FTH/FTL)-mediated iron sequestration, and maintaining redox balance through FSP1–CoQ10-dependent lipid repair. Reproduced from Cheng et al., 2023, Antioxidants, with permission (). GFAP, glial fibrillary acidic protein; BACH1, BTB and CNC homology 1; FTH1, ferritin heavy chain 1; DAPI, 4′,6-diamidino-2-phenylindole; ROS, reactive oxygen species; β-ACTIN, beta-actin; WT, wild type; Nrf2-/-, nuclear factor erythroid 2–related factor 2 knockout; DMF, dimethyl fumarate; FTL, ferritin light chain; xCT, cystine/glutamate antiporter (SLC7A11); GPX4, glutathione peroxidase 4; FSP1, ferroptosis suppressor protein 1; Fe²+, ferrous iron; Nissl, Nissl staining; dpi, days post injury; LAS, low-altitude sham; LAT, low-altitude TBI; HAS, high-altitude sham; HAT, high-altitude TBI; Tubulin, structural protein used as internal control.

2.3 Disease-specific differences in ferroptosis across neurological disorders

Ferroptosis manifests with disease-specific features across neurological conditions. In ischemic stroke, cerebral ischemia/reperfusion rapidly triggers iron accumulation, lipid peroxidation, and GPX4/SLC7A11 depression; the ferroptosis inhibitor ferrostatin-1 reduces infarct volume and improves neurobehavioral outcomes in middle cerebral artery occlusion (MCAO) models, consistent with an Protein kinase B/Glycogen Synthase Kinase 3 Beta (AKT/GSK3β)-dependent protection (). In hemorrhagic contexts, hemin/hemoglobin drives a variant of neuronal ferroptosis with distinct signaling; pharmacologic inhibition and ferroptosis blockers mitigate injury in ICH models, and in subarachnoid hemorrhage, liproxstatin-1 preserves GPX4, downregulates ACSL4/COX-2, and attenuates neurological deficits (, ). In traumatic brain injury, ferroptosis contributes to secondary damage; ferrostatin-1 decreases lesion volume and improves long-term sensorimotor/cognitive outcomes (). In Alzheimer’s disease, neuronal loss of the iron exporter ferroportin precipitates ferroptosis and memory impairment, while liproxstatin-1/ferrostatin-1 rescue Aβ-induced neuronal death and cognitive defects (). In Parkinson’s disease, dopamine oxidation promotes GPX4 ubiquitination and loss, provoking dopaminergic neuron ferroptosis; restoring GPX4 ameliorates degeneration and motor deficits (). In multiple sclerosis (MS), patient lesions/Cerebrospinal Fluid (CSF) show iron overload and oxidized phospholipids; late-stage treatment with a ferroptosis inhibitor (UAMC-3203) or delayed anti-ferroptotic therapy in chronic experimental autoimmune encephalomyelitis (EAE) ameliorates disease severity and pathology, underscoring ferroptosis as a targetable driver of progressive MS (, ).

These disease-specific patterns suggest that any exosome-based intervention should be disease-tailored to the dominant ferroptosis drivers in each condition, which we consider next.

3 Exosome-mediated modulation of ferroptosis in neurological disorders

3.1 Stem cell-derived exosomes in modulating ferroptosis in neural cells

Exosomes derived from mesenchymal stem cells (MSCs) and other stem cell populations exhibit notable potential in regulating ferroptotic signaling through delivery of regulatory RNAs and proteins () (). Recent studies have uncovered distinct molecular mechanisms through which these exosomes alleviate oxidative stress, modulate iron homeostasis, and enhance antioxidant defenses in the CNS.

3.1.1 IL-1β-primed MSC-derived exosomes target the HSPA5/GPX4 axis in intracerebral hemorrhage

Li et al. (2024) reported that exosomes derived from MSCs preconditioned with interleukin-1β (IL-1β-Exos) significantly inhibited neuronal ferroptosis in a rat model of intracerebral hemorrhage (ICH). Mechanistically, these exosomes upregulated GPX4, a critical lipid peroxidation-detoxifying enzyme, and heat shock protein A5 (HSPA5), a molecular chaperone that stabilizes GPX4 by preventing its degradation. Additionally, IL-1β-Exos downregulated iron metabolism-related genes, thereby reducing the intracellular labile iron pool and limiting ROS accumulation. Enhanced activity of antioxidant enzymes, including superoxide dismutase (SOD), GSH peroxidase (GSH-Px), and increased GSH levels—further reinforced the suppression of ferroptotic cell death ().

3.1.2 BMMSC-derived exosomes alleviate SCI via IL-17 pathway suppression

Tang et al. (2024) reported that BMMSC-derived exosomes could mitigate ferroptosis and inflammatory injury in spinal cord injury models, partly via modulation of the IL-17 signaling pathway (). These findings highlight the capacity of BMMSC-Exos to modulate immune–oxidative interplay in ferroptotic cascades and provide insight into their multifaceted neuroprotective mechanisms. Similarly, ADSC-derived exosomes have also been demonstrated to suppress ferroptotic cell death through antioxidant and metabolic reprogramming mechanisms, further emphasizing the therapeutic diversity of stem cell–derived exosomal cargos.

3.1.3 miRNA- and lncRNA-enriched exosomes regulate ferroptosis via multiple signaling axes

In addition to protein regulation, exosomal non-coding RNAs have emerged as powerful post-transcriptional modulators of ferroptosis:

miR-367-3p, delivered via umbilical cord MSC-derived exosomes, targets enhancer of zeste homolog 2 (EZH2), relieving transcriptional repression of SLC7A11, thereby restoring cystine uptake and GPX4 activity (, ).

miR-194, from MSC-derived exosomes, suppresses Bach1, activating the Nrf2/HO-1 antioxidant axis, leading to reduced iron-induced oxidative injury (, ).

lncGm36569, enriched in exosomes, acts as a ceRNA for miR-5627-5p, upregulating FSP1, a GPX4-independent ferroptosis inhibitor that catalyzes CoQ10-mediated lipid antioxidant activity (68).

miR-19b-3p, carried by adipose-derived stem cell (ADSC) exosomes, targets iron regulatory protein 2 (IRP2), restoring iron balance via upregulation of FPN and downregulation of TfR1, thus reducing ROS and ferroptosis in ICH models (69).

In addition, the tissue origin of MSCs significantly shapes the properties of their exosomes. UCMSC-Exos are obtained non-invasively, with high yield and low immunogenicity, and are enriched in antioxidant miRNAs that enhance GPX4/SLC7A11 signaling (70, 71). BMMSC-Exos, though historically the most studied, require invasive bone marrow aspiration and show donor variability; they carry regulatory miRNAs such as miR-367-3p that suppress ferroptosis through iron metabolism pathways (72). ADSC-Exos are abundant and easily harvested, enriched in metabolic and anti-inflammatory miRNAs, and have been shown to alleviate ferroptosis by activating the NRF2/SLC7A11/GPX4 pathway or modulating the FXR2/ATF3/SLC7A11 axis (73, 74).

As summarized in Table 1, stem cell–derived exosomes from multiple sources converge on HSPA5/GPX4, IL-17/GPX4/SLC7A11/ACSL4, and ncRNA-mediated axes to alleviate ferroptosis across CNS injury models.

Table 1

Exosome sourceKey cargoTarget molecule/pathwayNeurological modelBiological effectsReferences
IL-1β-primed MSCsHSPA5, GPX4HSPA5/GPX4 axisIntracerebral HemorrhageEnhances GPX4 stability, reduces Fe²+ and ROS, increases SOD/GSH, inhibits ferroptosis()
Bone Marrow MSCsGPX4, xCT, ↓ACSL4IL-17/GPX4/xCT/ACSL4SCIReduces oxidative stress and inflammation, restores redox homeostasis, suppresses ferroptosis()
Umbilical Cord MSCsmiR-367-3pEZH2/SLC7A11NeurodegenerationPromotes xCT expression, enhances GSH synthesis, inhibits lipid peroxidation()
MSCsmiR-194Bach1/Nrf2/HO-1OGD/R injuryActivates antioxidant transcriptional response, protects neurons()
MSCslncGm36569miR-5627-5p/FSP1Acute Spinal Cord Injury (ASCI)Enhances CoQ10-mediated detoxification, mitigates ROS and ferroptosis(68)
ADSCsmiR-19b-3pIRP2/FPN/TfR1Intracerebral HemorrhageReduces iron overload, improves antioxidant capacity, prevents ferroptosis-induced neural injury(69)

Stem cell-derived exosomes in the regulation of ferroptosis in the CNS.

MSCs, mesenchymal stem cells; ADSCs, adipose-derived stem cells; ASCI, acute spinal cord injury; SCI, spinal cord injury; OGD/R, oxygen-glucose deprivation/reperfusion; ICH, intracerebral hemorrhage; IL-1β, interleukin-1β; HSPA5, heat shock protein A5; GPX4, glutathione peroxidase 4; FSP1, ferroptosis suppressor protein 1; CoQ10, coenzyme Q10; FPN, ferroportin; TfR1, transferrin receptor 1; FTH1, ferritin heavy chain 1; IRP2, iron regulatory protein 2; ROS, reactive oxygen species; SOD, superoxide dismutase; GSH, glutathione; ACSL4, acyl-CoA synthetase long-chain family member 4; xCT (SLC7A11), cystine/glutamate antiporter; EZH2, enhancer of zeste homolog 2; Bach1, BTB and CNC homology 1; Nrf2, nuclear factor erythroid 2–related factor 2; HO-1, heme oxygenase-1; lncGm36569, long non-coding RNA Gm36569; miR-5627-5p, microRNA-5627-5p.

3.2 Comparative roles of exosomes from different cellular origins in ferroptosis regulation

Despite their heterogeneity, exosomes from different cellular sources share common ferroptosis-regulatory features. Most vesicles alleviate oxidative stress by upregulating GPX4/SLC7A11, suppressing lipid peroxidation, and limiting iron overload.

However, source-specific differences are evident. MSC-Exos display broad-spectrum protection, with IL-1β-preconditioned vesicles acting via the HSPA5/GPX4 axis, and engineered ADSC-Exos targeting microglia through the FXR2/ATF3/SLC7A11 pathway (, 74). Microglia-Exos are strongly phenotype dependent: M2-derived vesicles suppress ferroptosis by delivering miR-124-3p to inhibit NCOA4/ferritinophagy or by activating FUNDC1 mitophagy, whereas M1-Exos may exert opposite effects (75, 76). Neuronal lineage exosomes are less studied, but NSC-Exos carrying CDC42 reduce ACSL4-driven ferroptosis in Parkinson’s models (77). In addition, astrocyte-derived exosomes preserve GPX4 and attenuate hemin-induced ferroptosis (78), while endothelial progenitor exosomes deliver miR-199a-3p to inhibit SP1, thereby suppressing endothelial ferroptosis (79).

Together, these findings indicate that exosomes form a cell-origin–specific yet complementary network against ferroptosis. Representative studies of exosomes from different cellular sources and their ferroptosis-regulatory mechanisms are outlined in Table 2.

Table 2

Exosome sourceKey cargoTarget molecule/pathwayFerroptosis-regulatory effectDistinctive featuresReferences
MSCsHSPA5-related proteins; FXR2→ATF3/SLC7A11HSPA5/GPX4; SLC7A11/GPX4Inhibit neuronal ferroptosis, reduce lipid peroxidationBroad protection; enhanced by IL-1β preconditioning; engineered ADSC-Exos target M2 microglia(, 74)
Microglia (M2)miR-124-3p; mitophagy-related cargoNCOA4/ferritinophagy; FUNDC1 mitophagySuppress ferritinophagy, activate mitophagy, attenuate neuronal ferroptosisStrong phenotype dependency; M2 protective, M1 may aggravate ferroptosis(75, 76)
Neuronal lineage (NSCs)CDC42ACSL4/lipid metabolismReduce ACSL4-driven ferroptosis; improve vascular and behavioral deficits in PDLimited direct evidence; suggest potential role of neuronal lineage exosomes(77)
AstrocytesHypoxia-preconditioned exosomal cargoGPX4 regulationMitigate hemin-induced neuronal ferroptosisEmerging evidence; first experimental proof of astrocyte-derived exosomes in ferroptosis(78)
Endothelial progenitors (EPCs)miR-199a-3pmiR-199a-3p → SP1Suppress endothelial ferroptosis; reduce lipid peroxidationEmphasize vascular protection; highlight peripheral–central crosstalk(79)

Representative studies on exosomes from different cellular origins in ferroptosis regulation.

MSCs, mesenchymal stem cells; ADSCs, adipose-derived stem cells; NSCs, neural stem cells; M1, M1-polarized macrophage/microglia; M2, M2-polarized macrophage/microglia; ADSC-Exos, adipose-derived stem cell exosomes; IL-1β, interleukin-1β; HSPA5, heat shock protein A5; GPX4, glutathione peroxidase 4; FXR2, fragile X mental retardation syndrome–related protein 2; ATF3, activating transcription factor 3; SLC7A11, solute carrier family 7 member 11; NCOA4, nuclear receptor coactivator 4; FUNDC1, FUN14 domain-containing protein 1; ACSL4, acyl-CoA synthetase long-chain family member 4; SP1, specificity protein 1; miR-124-3p, microRNA-124-3p; miR-199a-3p, microRNA-199a-3p.

4 The molecular mechanism underlying exosome-mediated modulation of ferroptosis in neurological injuries

4.1 Ferroptosis-related signaling pathways as core targets

Ferroptosis is governed by several critical signaling pathways, including the GPX4–GSH axis, the xCT–SLC7A11 system, the FSP1–CoQ10 pathway, the DHODH–CoQ10 mitochondrial mechanism, and the Nrf2/HO-1 antioxidant response. These interconnected cascades collectively determine neuronal susceptibility to ferroptosis by controlling iron homeostasis, lipid peroxidation, and oxidative defense.

4.2 Exosomal miRNAs orchestrating ferroptosis via signaling pathways

Exosomal miRNAs orchestrate ferroptosis regulation by targeting specific nodes in iron metabolism, lipid peroxidation, and antioxidant defense (80). In oxygen-glucose deprivation/reperfusion (OGD/R)-injured hippocampal neurons, exosome-delivered miR-124 from M2 microglia suppresses NCOA4, limiting ferritinophagy and intracellular iron release, thereby reducing ROS and MDA while restoring GSH and cell viability (75). In TBI and ischemia models, miR-124 also downregulates ubiquitin-specific protease 14 (USP14), mitigating injury-related inflammation and proteotoxic stress (81).

miR-367-3p, enriched in human umbilical cord mesenchymal stem cells (hUCMSC) -derived exosomes, inhibits EZH2, relieving transcriptional repression on SLC7A11 (82). This enhances cystine uptake and GSH synthesis, reinforcing the xCT–GSH–GPX4 axis and suppressing ferroptosis. This mechanism is implicated in models of multiple sclerosis and AD.

Additionally, exosomal miR-484 from skeletal muscle stem cells inhibits ACSL4, indirectly enhancing GPX4 activity by limiting PUFA incorporation into phospholipids, thereby attenuating iron-dependent lipid peroxidation (83).

These findings collectively define a modular system wherein distinct exosomal miRNAs modulate upstream and downstream ferroptosis drivers with high specificity and translational potential.

4.3 Exosomal proteins and lncRNAs in pathway-specific ferroptosis regulation

Exosomal non-coding RNAs and stress-response proteins enable post-transcriptional and protein-level intervention in ferroptotic signaling. In an ICH model, IL-1β-induced MSC-derived exosomes upregulate HSPA5, which stabilizes GPX4, preventing lipid peroxide accumulation. These exosomes concurrently reduce Fe2+, MDA, and ROS, and restore enzymatic antioxidants including SOD and GSH-Px ().

In SCI, BMMSC-derived exosomes modulate ferroptosis through simultaneous suppression of IL-17 signaling and rebalancing of lipid metabolism. They upregulate GPX4 and SLC7A11, downregulate ACSL4, and attenuate inflammation by decreasing IL-17A, Act1, and IL-17RA expression ().

The lncGm36569/miR-5627-5p/FSP1 axis, delivered via MSC-derived exosomes, activates a GPX4-independent ferroptosis checkpoint. By derepressing FSP1, it facilitates CoQ10 recycling and membrane repair under oxidative stress, notably in ASCI models (68).

Exosomes from LPS-stimulated M1 microglia reduce GPX4, SLC7A11, and FTH1 in neurons, exacerbating ferroptotic sensitivity (84, 85). Transcriptomic data confirm these M1-derived vesicles drive ferroptosis-linked transcriptional changes, especially in genes controlling iron handling and lipid ROS metabolism (86).

Thus, exosomal cargo from differently primed stem or immune cells can exert either protective or deleterious ferroptotic effects, dependent on the inflammatory or reparative state of the donor cell.

4.4 Exosome-mediated antioxidant signaling

Beyond direct targeting of ferroptosis regulators, exosomal cargos activate systemic antioxidant networks that confer neuroprotection (87). In ischemic stroke models, BMSC-derived exosomes enhance Nrf2 nuclear translocation and downstream HO-1, SOD, and catalase expression, restoring redox homeostasis and inhibiting ferroptotic injury (88, 89).

In TBI, hUCMSC exosomes upregulate lncRNA TUBB6, which modulates Nrf2-dependent transcription and suppresses ACSL4, while maintaining GPX4 expression. Mitochondrial morphology and lipid peroxide levels are normalized, indicating structural and biochemical ferroptosis suppression (71).

In aging-related delayed neurocognitive recovery, exosomes boost SIRT1, facilitating Nrf2 nuclear translocation and subsequent HO-1 activation. This reduces free iron, lipid oxidation, and neuronal loss, ultimately improving cognitive outcomes (90). These pathways converge on Nrf2’s master regulatory role in coordinating cellular defense against oxidative ferroptotic damage, with exosomes acting as both inducers and amplifiers of this response. A schematic illustration of these exosome-mediated pathways is presented in Figure 4.

Figure 4

5 Challenges and application prospects

Exosomes have emerged as promising therapeutic agents for neurological disorders due to their ability to modulate ferroptosis. However, their clinical application faces several challenges that need to be addressed. There exists a diverse array of exosome species, with complex sources. Based on the presence or absence of artificial modifications, exosomes can be categorized into engineered and natural exosomes. Natural exosomes are further classified into those derived from animals and those derived from plants (91). The therapeutic efficacy and safety assessment of exosomes sourced from various origins currently lack systematic analysis. Furthermore, research on the mechanisms underlying exosome function is still insufficient; more in-depth investigations are required regarding cellular uptake, signaling pathways, and targets associated with these vesicles. The prevailing technology for isolating exosomes—ultracentrifugation—can yield them to a certain extent; however, this method often results in low purity levels, requires expensive equipment, and may inadvertently damage the exosomes or lead to their loss (92). Additionally, the relatively limited clinical application of exosome-based therapeutics and inadequate ethical support concerning some human-derived exosomes present significant barriers to translating research outcomes into practical applications.

5.1 Biological stability and immune safety

In vivo, exosomes are susceptible to rapid clearance by the mononuclear phagocyte system, limiting their therapeutic efficacy (93). Moreover, exosomes may carry immunogenic molecules that trigger immune responses (94).

Seohyun Kim et al. modified exosomes using signal regulatory protein alpha(SIRPα) variants to enhance their ability to evade immune detection and prolong their circulation time. The SIRP-EV achieves active immune escape by mimicking the CD47-SIRPα immune checkpoint signal and significantly extends circulation time through the optimization of surface charge and protein corona control, which reduces non-target retention (95).

A study conducted by the University of Toledo in Toledo, Ohio, USA, demonstrated a dual-mode synergy of “targeting + escape”—where the CD47p110–130 peptide facilitates “escape escort”, and the Arg-Gly-Asp(RGD) peptide provides “targeting guidance”. ExoSmart overcomes the limitations of traditional exosome delivery, presenting a new paradigm for the precise treatment of solid tumors, such as pancreatic cancer (96).

Advanced separation and purification techniques can diminish the presence of immunogenic contaminants, thereby improving the safety and efficacy of exosome-based therapies (97). Furthermore, it was discovered that combining exosomes with biomaterials, such as hydrogels, can facilitate local and sustained release, enhancing their therapeutic effects while minimizing systemic clearance (98–100).

5.2 BBB penetration

The BBB presents a significant obstacle for the delivery of therapeutic agents to the CNS. Although exosomes have inherent abilities to cross the BBB, their efficiency remains suboptimal (101). Engineering exosomes with targeting ligands, such as rabies virus glycoprotein peptides that bind to nicotinic acetylcholine receptors, can enhance BBB penetration (102). Exosomes enriched with miRNA have been demonstrated to transiently enhanceBBB permeability by down-regulating tight junction proteins, such as claudin-5 (103). Additionally, external stimuli like focused ultrasound have been employed to transiently disrupt the BBB, facilitating exosome entry (104, 105).

5.3 Targeted delivery efficiency

Achieving targeted delivery of exosomes to specific neuronal populations is crucial for maximizing therapeutic outcomes and minimizing off-target effects (106). Surface functionalization of exosomes with antibodies or ligands specific to neuronal markers, such as L1 cell adhesion molecule (L1CAM) or neural cell adhesion molecule(NCAM), can enhance targeting specificity (74, 107). Furthermore, magnetic guidance using superparamagnetic iron oxide nanoparticles incorporated into exosomes allows for spatial control of delivery under an external magnetic field (108). Extracellular vesicles in engineering present a promising option for targeted delivery. A monoclonal antibody that targets the growth-associated protein-43 (GAP43) has been employed to direct extracellular vesicles towards the extracellular environment of damaged neurons in an ischemic stroke model. This approach ensures that the extracellular vesicles accurately deliver their contents to the specific neuronal population intended (109).

5.4 Exosome engineering for enhanced therapeutic efficacy

Advancements in exosome engineering have enabled the incorporation of therapeutic molecules, including miRNAs, proteins, and small molecules, to modulate ferroptosis pathways effectively (110). For instance, loading exosomes with miR-124 can downregulate NCOA4, reducing ferritinophagy and iron accumulation. Similarly, exosomes enriched with miR-367-3p can suppress EZH2, leading to upregulation of SLC7A11 and enhanced GSH synthesis. Prof. Li Xukun and his colleagues from Wenzhou Medical University have conducted research on the utilization of exosomes for drug loading and targeted delivery through genetic engineering and chemical modification. They successfully delivered Fibroblast Growth Factor 20(FGF20) for the treatment of ischemic stroke and collaborated with endogenous miRNAs, such as miR-181b-5p, to enhance neural plasticity (111). These modifications can be achieved through electroporation, transfection, or incubation methods ().

5.5 Standardization and scalability of exosome production

For clinical translation, standardized and scalable production of exosomes is essential. Current isolation methods, such as ultracentrifugation and size-exclusion chromatography, have limitations in yield and purity. Emerging techniques like tangential flow filtration and microfluidic-based isolation offer improved scalability and consistency (112, 113). Establishing Good Manufacturing Practice compliant protocols will be critical for regulatory approval and widespread clinical use.

A study demonstrates that the combination of Tangential flow filtration (TFF) and Size exclusion chromatography(SEC) can enhance particle concentration by 16.9 times, establishing it as a viable method for mass production (114). Furthermore, researchers from the Department of Pharmacy at Yonsei University in Korea have discovered that hypotonic stimulation and cytochalasin-B therapy can significantly increase exosome yield and drug-carrying capacity (115). Future improvements and translational prospects for exosome-based therapies are depicted in Figure 5.

Figure 5

6 Safety considerations for exosome-based therapies

6.1 Potential safety risks

6.1.1 Off-target effects

Extracellular vesicle surface targeting ligands (such as RVG peptides) may bind to non target cell receptors (such as peripheral nerve nAChR), leading to drug delivery to non target tissues (such as heart, muscle) (102). In addition, the regulatory RNA carried by it (such as miR-181b-5p) may interfere with the normal signaling pathway of receptor cells (such as the PTEN/PI3K-AKT pathway), affecting cell metabolism or proliferation. In acute lymphoblastic leukemia (ALL), miR-181b-5p carried by exosomes is internalized into leukemia cells, upregulated in expression, promoting cell proliferation, migration, and invasion, while inhibiting cell apoptosis (116). Such off target effects may induce organ toxicity, metabolic disorders, or tumor risk.

6.1.2 Immunogenicity concerns

The immune system itself has inherent immunogenicity. Extracellular vesicle membrane proteins may activate host immune responses and trigger a storm of inflammatory factors (117, 118). Residual donor cell DNA/RNA may trigger the TLR signaling pathway, leading to dendritic cell activation and adaptive immune response. In animal models, serum complement activation and neutrophil infiltration can usually be observed after injection of unpurified extracellular vesicles (119).

6.2 Strategies to mitigate safety risks​​

6.2.1 Donor cell screening and modification​

To effectively screen donor cells for practical applications, it is essential to select low immunogenicity cell sources, such as autologous MSCs or immune-exempt induced pluripotent stem cells (iPSCs), while avoiding the expression of allogeneic major histocompatibility complex (MHC) molecules. Gene editing techniques, such as CRISPR-Cas9, can be employed to knock out immunogenic genes, exemplified by silencing the B2M gene to eliminate MHC-I expression, thereby reducing immunogenic interference from the source (120–122). Furthermore, engineering modifications, including the display of immune evasion molecules on the cell surface, inhibition of macrophage phagocytosis, introduction of tissue-specific targeting peptides, and enhancement of brain-specific delivery, can also mitigate common risks associated with donor cell utilization (123).

6.2.2 Exosome purification and quality control

During the extraction process of extracellular vesicles, free proteins and apoptotic bodies are typically removed using ultracentrifugation in conjunction with size exclusion chromatography (124, 125). Additionally, anti-CD63/CD81 antibody columns may be employed for purification to ensure the uniformity of exosome subpopulations (126, 127). Furthermore, the quality of extracellular vesicles produced from different batches was monitored through nanoparticle tracking analysis (NTA), Western blotting (WB), and endotoxin level assessments. Together, these procedures establish a standardized quality-control framework that improves batch-to-batch consistency and regulatory readiness.

6.2.3 Off target effect control and loading safety

The quality of extracellular vesicles (EVs) produced from different batches can be significantly enhanced through advanced separation techniques such as size exclusion chromatography (SEC) and density gradient ultracentrifugation. These methods effectively remove unwanted proteins and cytokines that may induce off-target effects. For instance, EV formulations that are depleted of soluble cytokines, such as VEGF-A and Monocyte chemoattractant protein 1 (MCP-1), exhibit enhanced immunomodulatory activity. Such purification techniques ensure that extracellular vesicles retain their therapeutic potential while minimizing adverse reactions to the greatest extent possible (128). Furthermore, electroporation or chemical transfection can be employed to load exogenous cargo onto exosomes. However, these technologies must be meticulously optimized to prevent damage to the EV membrane or alterations in functionality. For example, the CRISPR ribonucleoprotein (RNP) complex was successfully encapsulated into EVs using a protein binding strategy, demonstrating high delivery efficiency (129). Additionally, it is crucial to avoid the direct loading of highly toxic drugs. The quality of the EVs was monitored through NTAandWB, and endotoxin level assessments. Optimized loading conditions and stringent release testing minimize off-target risks while preserving vesicle integrity and therapeutic function, complementing the purification workflow described above.

6.3 Clinical translation framework

Before clinical application, drugs typically undergo a comprehensive safety evaluation that primarily assesses their immunotoxicity through the detection of serum complement activity, lymphocyte subsets, and cytokine profiles. Furthermore, organ toxicity is evaluated through histopathological examinations of major organs and long-term monitoring for carcinogenicity. Additionally, administering drugs based on particle count rather than protein dosage ensures consistent quality across batches. These methods are essential for evaluating and validating safety prior to clinical use.

7 Conclusions

Ferroptosis has emerged as a key driver of neuronal death in a wide spectrum of neurological disorders, from acute brain injuries to chronic neurodegeneration. In this context, exosomes offer a unique and highly adaptable platform for targeted therapeutic intervention. By leveraging their innate ability to cross the BBB and deliver functional cargo such as regulatory miRNAs, lncRNAs, and proteins, exosomes can modulate core ferroptosis pathways, such as the GPX4-GSH axis, ferritinophagy, and lipid peroxidation, at both transcriptional and post-translational levels. Engineered exosomes further expand this potential through surface ligand modification, cargo enrichment, and responsive delivery systems, enabling precise spatial and molecular targeting within injured neural tissues. Despite this promise, substantial barriers remain, including limited in vivo stability, heterogeneity in large-scale production, and the need for validated clinical-grade manufacturing and safety frameworks. Moving forward, the convergence of nanotechnology, molecular neuroscience, and synthetic biology will be essential to transform exosome-based ferroptosis modulation from a preclinical concept into a clinically actionable therapy. With continued interdisciplinary innovation, exosomes are poised to become a next-generation strategy for combating ferroptosis-driven brain injury and advancing the frontier of neuroprotective medicine.

Statements

Author contributions

XB: Writing – original draft, Writing – review & editing. LC: Writing – original draft, Visualization, Formal analysis. HY: Writing – original draft, Visualization. YX: Writing – original draft. LiL: Writing – original draft. LL: Writing – review & editing. HW: Writing – original draft. RC: Writing – original draft. YC: Writing – review & editing. DS: Conceptualization, Writing – review & editing. CZ: Funding acquisition, Conceptualization, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research and/or publication of this article. This work was funded by the Summit Advancement Disciplines of Zhejiang Province (Wenzhou Medical University - Pharmaceutics), and Scientific Research Cultivation Project of the College of Life and Environmental Sciences, Wenzhou University (SHPY2025010).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Generative AI statement

The author(s) declare that Generative AI was used in the creation of this manuscript only for language polishing of the text. All content, including ideas, interpretations, and conclusions, was conceived, written, and verified by the authors.

Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Glossary

  • AD

    Alzheimer’s disease

  • PD

    Parkinson’s disease

  • TBI

    Traumatic brain injury

  • ADI

    Alzheimer’s Disease International

  • ROS

    Reactive oxygen species

  • BBB

    Blood–brain barrier

  • CNS

    Central nervous system

  • GPX4

    Glutathione peroxidase 4

  • GSH

    Glutathione

  • Fe²⁺

    Ferrous iron

  • Fe³⁺

    Ferric iron

  • OH

    Hydroxyl radicals

  • FPN

    Ferroportin

  • HIFs

    Hypoxia-inducible factors

  • NTBI

    Non-transferrin-bound iron

  • NCOA4

    Nuclear receptor coactivator 4

  • PUFAs

    Polyunsaturated fatty acids

  • ACSL4

    Acyl-CoA synthetase long-chain family member 4

  • ACSL3

    Acyl-CoA synthetase long-chain family member 3

  • LPCAT3

    Lysophosphatidylcholine acyltransferase 3

  • PUFA-OOH

    Lipid hydroperoxides

  • MUFAs

    Monounsaturated fatty acids

  • SLC7A11/xCT

    Solute carrier family 7 member 11

  • SLC3A2

    Solute carrier family 3 member 2

  • SLC25A11

    Solute carrier family 25 member 11

  • SLC25A10

    Solute carrier family 25 member 10

  • MDA

    Malondialdehyde

  • 4-HNE

    4-Hydroxynonenal

  • MSCs

    Mesenchymal stem cells

  • ICH

    Intracerebral hemorrhage

  • HSPA5

    Heat shock protein A5

  • IL-1β

    Interleukin-1β

  • SOD

    Superoxide dismutase

  • GSH-Px

    Glutathione peroxidase

  • BMMSC-Exos

    Exosomes derived from bone marrow MSCs

  • ADSCs

    Adipose-derived stem cells

  • ASCI

    Acute spinal cord injury

  • FSP1

    Ferroptosis suppressor protein 1

  • hUCMSCs

    Human umbilical cord mesenchymal stem cells

  • EZH2

    Enhancer of zeste homolog 2

  • CoQ10

    Coenzyme Q10

  • CoQH₂

    Coenzyme Q H₂

  • IRP2

    Iron regulatory protein 2

  • FTH1

    Ferritin heavy chain 1

  • BMSCs

    Marrow-derived mesenchymal stem cells

  • Nrf2

    Nuclear factor erythroid 2–related factor 2

  • KEAP1

    Kelch-like ECH-associated protein 1

  • HO-1

    Heme oxygenase-1

  • FGF2

    Fibroblast growth factor 2

  • DHODH

    Dihydroorotate dehydrogenase

  • DMF

    Dimethyl fumarate

  • Bach1

    BTB and CNC homology 1

  • PTGS2

    Prostaglandin-endoperoxide synthase 2

  • miRNA

    MicroRNA

  • lncRNA

    Long non-coding RNA

  • PDENs

    Plant-derived exosome-like nanoparticles

  • VEGF

    Vascular endothelial growth factor

  • VEGF-A

    Vascular endothelial growth factor A

  • PINK1

    PTEN-induced kinase 1

  • MFF

    Mitochondrial fission factor

  • FUNDC1

    FUN14 domain containing 1

  • NADPH

    Nicotinamide adenine dinucleotide phosphate

  • RNS

    Reactive nitrogen species

  • mPTP

    Mitochondrial permeability transition pore

  • DOELNs

    Dendrobium officinale exosome-like nanoparticles

  • EVs

    Extracellular vesicles

  • DOX

    Doxorubicin

  • TNF-α

    Tumor necrosis factor alpha

  • IL-6

    Interleukin-6

  • IL-17

    Interleukin-17

  • IL-17RA

    Interleukin-17 receptor A

  • eIF2α

    Eukaryotic translation initiation factor 2α

  • OGD/R

    Oxygen–glucose deprivation/reoxygenation

  • rTMS

    Repetitive transcranial magnetic stimulation

  • ATF3

    Activating transcription factor 3

  • FXR2

    Fragile X mental retardation syndrome-related protein 2

  • MCP-1

    Monocyte chemoattractant protein 1

  • EVs

    Extracellular vesicles

  • RNP

    Ribonucleoprotein

  • CRISPR

    Clustered regularly interspaced short palindromic repeats

  • NTA

    Nanoparticle tracking analysis

  • WB

    Western blot

  • TFF

    Tangential flow filtration

  • SEC

    Size exclusion chromatography

  • FGF20

    Fibroblast growth factor 20

  • SIRPα

    Signal regulatory protein alpha

  • RGD

    Arg-Gly-Asp

  • L1CAM

    L1 cell adhesion molecule

  • NCAM

    Neural cell adhesion molecule

  • GAP43

    Growth-associated protein-43

  • USP14

    Ubiquitin-specific protease 14

  • MCAO

    Middle cerebral artery occlusion

  • AKT

    Protein kinase B

  • GSK3β

    Glycogen synthase kinase 3 beta

  • MS

    Multiple sclerosis

  • CSF

    Cerebrospinal Fluid

  • EAE

    Experimental autoimmune encephalomyelitis

References

  • 1

    GBD 2019 North Africa and the Middle East Neurology Collaborators. The burden of neurological conditions in north Africa and the Middle East, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019. Lancet Glob Health. (2024) 12:e960–82. doi: 10.1016/S2214-109X(24)00093-7

  • 2

    GBD 2021 Nervous System Disorders Collaborators. Global, regional, and national burden of disorders affecting the nervous system, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. (2024) 23:344–81. doi: 10.1016/S1474-4422(24)00038-3

  • 3

    YanHFZouTTuoQZXuSLiHBelaidiAAet al. Ferroptosis: mechanisms and links with diseases. Signal Transduct Target Ther. (2021) 6:49. doi: 10.1038/s41392-020-00428-9

  • 4

    FeiginVLAbateMDAbateYHAkinyemiROAlahdabFAlipourVet al. Global, regional, and national burden of stroke and its risk factors, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Neurol. (2024) 23:973–1003. doi: 10.1016/S1474-4422(24)00369-7

  • 5

    MaasAIRMenonDKManleyGTAbramsMÅkerlundCAndelicNet al. Traumatic brain injury: progress and challenges in prevention, clinical care, and research. Lancet Neurol. (2022) 21:1004–60. doi: 10.1016/S1474-4422(22)00309-X

  • 6

    Alzheimer's Disease International (ADI). (2024). World Alzheimer Report 2024: Global Changes in Attitudes to Dementia. London (UK): Alzheimer’s Disease International. Available online at: https://www.alzint.org/resource/world-alzheimer-report-2024/ (Accessed March 6, 2025).

  • 7

    AngelovaPREsterasNAbramovAY. Mitochondria and lipid peroxidation in the mechanism of neurodegeneration: Finding ways for prevention. Med Res Rev. (2021) 41:770–84. doi: 10.1002/med.21712

  • 8

    SunSShenJJiangJWangFMinJ. Targeting ferroptosis opens new avenues for the development of novel therapeutics. Signal Transduct Target Ther. (2023) 8:372. doi: 10.1038/s41392-023-01606-1

  • 9

    TuoQZLiuYXiangZYanHFZouTShuYet al. Thrombin induces ACSL4-dependent ferroptosis during cerebral ischemia/reperfusion. Signal Transduct Target Ther. (2022) 7:1–15. doi: 10.1038/s41392-022-00917-z

  • 10

    GeYWangTHuQWuXCaiYXieWet al. Adiponectin ameliorates traumatic brain injury-induced ferroptosis through AMPK- ACC1 signaling pathway. Brain Behav Immun. (2025) 126:160–75. doi: 10.1016/j.bbi.2025.01.020

  • 11

    RyanSKZelicMHanYTeepleEChenLSadeghiMet al. Microglia ferroptosis is regulated by SEC24B and contributes to neurodegeneration. Nat Neurosci. (2023) 26:12–26. doi: 10.1038/s41593-022-01221-3

  • 12

    BaoWDPangPZhouXTHuFXiongWChenKet al. Loss of ferroportin induces memory impairment by promoting ferroptosis in Alzheimer’s disease. Cell Death Differ. (2021) 28:1548–62. doi: 10.1038/s41418-020-00685-9

  • 13

    KalluriRLeBleuVS. The biology, function, and biomedical applications of exosomes. Science. (2020) 367:eaau6977. doi: 10.1126/science.aau6977

  • 14

    IsaacRReisFCGYingWOlefskyJM. Exosomes as mediators of intercellular crosstalk in metabolism. Cell Metab. (2021) 33:1744–62. doi: 10.1016/j.cmet.2021.08.006

  • 15

    PathanMFonsekaPChittiSVKangTSanwlaniRVan DeunJet al. Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. (2019) 47:D516–9. doi: 10.1093/nar/gky1029

  • 16

    SalunkheSDheerajBasakMChitkaraDMittalA. Surface functionalization of exosomes for target-specific delivery and in vivo imaging & tracking: Strategies and significance. J Controlled Release. (2020) 326:599–614. doi: 10.1016/j.jconrel.2020.07.042

  • 17

    YangZShiJXieJWangYSunJLiuTet al. Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat BioMed Eng. (2019) 4:69–83. doi: 10.1038/s41551-019-0485-1

  • 18

    DelilaLNebieOLeNTNTimmermanKLeeDYWuYWet al. Neuroprotective effects of intranasal extracellular vesicles from human platelet concentrates supernatants in traumatic brain injury and Parkinson’s disease models. J BioMed Sci. (2024) 31:87. doi: 10.1186/s12929-024-01072-z

  • 19

    RuQLiYXieWDingYChenLXuGet al. Fighting age-related orthopedic diseases: focusing on ferroptosis. Bone Res. (2023) 11:12. doi: 10.1038/s41413-023-00247-y

  • 20

    JiangXStockwellBRConradM. Ferroptosis: mechanisms, biology and role in disease. Nat Rev Mol Cell Biol. (2021) 22:266–82. doi: 10.1038/s41580-020-00324-8

  • 21

    DixonSJLembergKMLamprechtMRSkoutaRZaitsevEMGleasonCEet al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. (2012) 149:1060–72. doi: 10.1016/j.cell.2012.03.042

  • 22

    DuttSHamzaIBartnikasTB. Molecular mechanisms of iron and heme metabolism. Annu Rev Nutr. (2022) 42:311–35. doi: 10.1146/annurev-nutr-062320-112625

  • 23

    StockwellBR. Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. (2022) 185:2401–21. doi: 10.1016/j.cell.2022.06.003

  • 24

    MastrogiannakiMMatakPMathieuJRRDelgaSMayeuxPVaulontSet al. Hepatic hypoxia-inducible factor-2 down-regulates hepcidin expression in mice through an erythropoietin-mediated increase in erythropoiesis. Haematologica. (2012) 97:827–34. doi: 10.3324/haematol.2011.056119

  • 25

    RoemhildKVon MaltzahnFWeiskirchenRKnüchelRVon StillfriedSLammersT. Iron metabolism: pathophysiology and pharmacology. Trends Pharmacol Sci. (2021) 42:640–56. doi: 10.1016/j.tips.2021.05.001

  • 26

    WetliHABuckettPDWessling-ResnickM. Small-molecule screening identifies the selanazal drug ebselen as a potent inhibitor of DMT1-mediated iron uptake. Chem Biol. (2006) 13:965–72. doi: 10.1016/j.chembiol.2006.08.005

  • 27

    ZhangZKodumuruVSviridovSLiuSChafeevMChowdhurySet al. Discovery of benzylisothioureas as potent divalent metal transporter 1 (DMT1) inhibitors. Bioorg Med Chem Lett. (2012) 22:5108–13. doi: 10.1016/j.bmcl.2012.05.129

  • 28

    MagtanongLKoPJToMCaoJYForcinaGCTarangeloAet al. Exogenous monounsaturated fatty acids promote a ferroptosis-resistant cell state. Cell Chem Biol. (2019) 26:420–432.e9. doi: 10.1016/j.chembiol.2018.11.016

  • 29

    MinottiGAustSD. The role of iron in oxygen radical mediated lipid peroxidation. Chem Biol Interact. (1989) 71:1–19. doi: 10.1016/0009-2797(89)90087-2

  • 30

    LeYZhangZWangCLuD. Ferroptotic cell death: new regulatory mechanisms for metabolic diseases. Endocr Metab Immune Disord - Drug Targets. (2021) 21:785–800. doi: 10.2174/1871530320666200731175328

  • 31

    CuiJWangYTianXMiaoYMaLZhangCet al. LPCAT3 is transcriptionally regulated by YAP/ZEB/EP300 and collaborates with ACSL4 and YAP to determine ferroptosis sensitivity. Antioxid Redox Signal. (2023) 39:491–511. doi: 10.1089/ars.2023.0237

  • 32

    DollSPronethBTyurinaYYPanziliusEKobayashiSIngoldIet al. ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chem Biol. (2017) 13:91–8. doi: 10.1038/nchembio.2239

  • 33

    XuYLiYLiJChenW. Ethyl carbamate triggers ferroptosis in liver through inhibiting GSH synthesis and suppressing Nrf2 activation. Redox Biol. (2022) 53:102349. doi: 10.1016/j.redox.2022.102349

  • 34

    ForcinaGCDixonSJ. GPX4 at the crossroads of lipid homeostasis and ferroptosis. Proteomics. (2019) 19:1800311. doi: 10.1002/pmic.201800311

  • 35

    DeshwalSOnishiMTatsutaTBartschTCorsERiedKet al. Mitochondria regulate intracellular coenzyme Q transport and ferroptotic resistance via STARD7. Nat Cell Biol. (2023) 25:246–57. doi: 10.1038/s41556-022-01071-y

  • 36

    DollSFreitasFPShahRAldrovandiMda SilvaMCIngoldIet al. FSP1 is a glutathione-independent ferroptosis suppressor. Nature. (2019) 575:693–8. doi: 10.1038/s41586-019-1707-0

  • 37

    BersukerKHendricksJMLiZMagtanongLFordBTangPHet al. The CoQ oxidoreductase FSP1 acts parallel to GPX4 to inhibit ferroptosis. Nature. (2019) 575:688–92. doi: 10.1038/s41586-019-1705-2

  • 38

    LvYLiangCSunQZhuJXuHLiXet al. Structural insights into FSP1 catalysis and ferroptosis inhibition. Nat Commun. (2023) 14:5933. doi: 10.1038/s41467-023-41626-7

  • 39

    Xavier Da SilvaTNSchulteCAlvesANMaricHMFriedmann AngeliJP. Molecular characterization of AIFM2/FSP1 inhibition by iFSP1-like molecules. Cell Death Dis. (2023) 14:281. doi: 10.1038/s41419-023-05787-z

  • 40

    MaoCLiuXZhangYLeiGYanYLeeHet al. DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer. Nature. (2021) 593:586–90. doi: 10.1038/s41586-021-03539-7

  • 41

    LiuJGuoZNYanXLHuangSRenJXLuoYet al. Crosstalk between autophagy and ferroptosis and its putative role in ischemic stroke. Front Cell Neurosci. (2020) 14:577403. doi: 10.3389/fncel.2020.577403

  • 42

    WangJWangZLiYHouYYinCYangEet al. Blood brain barrier-targeted delivery of double selenium nanospheres ameliorates neural ferroptosis in Alzheimer’s disease. Biomaterials. (2023) 302:122359. doi: 10.1016/j.biomaterials.2023.122359

  • 43

    TanLXieJLiaoCLiXZhangWCaiCet al. Tetrahedral framework nucleic acids inhibit Aβ-mediated ferroptosis and ameliorate cognitive and synaptic impairments in Alzheimer’s disease. J Nanobiotechnology. (2024) 22:682. doi: 10.1186/s12951-024-02963-x

  • 44

    AnXHeJXiePLiCXiaMGuoDet al. The effect of tau K677 lactylation on ferritinophagy and ferroptosis in Alzheimer’s disease. Free Radic Biol Med. (2024) 224:685–706. doi: 10.1016/j.freeradbiomed.2024.09.021

  • 45

    Mahoney-SánchezLBouchaouiHAytonSDevosDDuceJADevedjianJC. Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease. Prog Neurobiol. (2021) 196:101890. doi: 10.1016/j.pneurobio.2020.101890

  • 46

    YanNZhangJ. Iron metabolism, ferroptosis, and the links with alzheimer’s disease. Front Neurosci. (2020) 13:1443. doi: 10.3389/fnins.2019.01443

  • 47

    QuLLiYLiuFLuoJYangYLiXet al. Microbiota-gut-brain axis dysregulation in alzheimer’s disease: multi-pathway effects and therapeutic potential. Aging Dis. (2024) 15:1108–31. doi: 10.14336/AD.2023.0823-2

  • 48

    WangBWangYZhangJHuCJiangJLiYet al. ROS-induced lipid peroxidation modulates cell death outcome: mechanisms behind apoptosis, autophagy, and ferroptosis. Arch Toxicol. (2023) 97:1439–51. doi: 10.1007/s00204-023-03476-6

  • 49

    SongXLongD. Nrf2 and ferroptosis: A new research direction for neurodegenerative diseases. Front Neurosci. (2020) 14:267. doi: 10.3389/fnins.2020.00267

  • 50

    ZilleMKaruppagounderSSChenYGoughPJBertinJFingerJet al. Neuronal death after hemorrhagic stroke in vitro and in vivo shares features of ferroptosis and necroptosis. Stroke. (2017) 48:1033–43. doi: 10.1161/STROKEAHA.116.015609

  • 51

    ZouPLiTCaoZWangXZhangYLiuJet al. High-altitude hypoxia aggravated neurological deficits in mice induced by traumatic brain injury via BACH1 mediating astrocytic ferroptosis. Cell Death Discov. (2025) 11:46. doi: 10.1038/s41420-025-02337-8

  • 52

    ChengHWangPWangNDongWChenZWuMet al. Neuroprotection of NRF2 against Ferroptosis after Traumatic Brain Injury in Mice. Antioxidants. (2023) 12:731. doi: 10.3390/antiox12030731

  • 53

    LiuXDuYLiuJChengLHeWZhangW. Ferrostatin-1 alleviates cerebral ischemia/reperfusion injury through activation of the AKT/GSK3β signaling pathway. Brain Res Bull. (2023) 193:146–57. doi: 10.1016/j.brainresbull.2022.12.009

  • 54

    ZilleMOses-PrietoJASavageSRKaruppagounderSSChenYKumarAet al. Hemin-induced death models hemorrhagic stroke and is a variant of classical neuronal ferroptosis. J Neurosci Off J Soc Neurosci. (2022) 42:2065–79. doi: 10.1523/JNEUROSCI.0923-20.2021

  • 55

    CaoYLiYHeCYanFLiJRXuHZet al. Selective ferroptosis inhibitor liproxstatin-1 attenuates neurological deficits and neuroinflammation after subarachnoid hemorrhage. Neurosci Bull. (2021) 37:535–49. doi: 10.1007/s12264-020-00620-5

  • 56

    XieBSWangYQLinYMaoQFengJFGaoGYet al. Inhibition of ferroptosis attenuates tissue damage and improves long-term outcomes after traumatic brain injury in mice. CNS Neurosci Ther. (2018) 25:465–75. doi: 10.1111/cns.13069

  • 57

    SunJLinXMLuDHWangMLiKLiSRet al. Midbrain dopamine oxidation links ubiquitination of glutathione peroxidase 4 to ferroptosis of dopaminergic neurons. J Clin Invest. (2023) 133:e165228. doi: 10.1172/JCI165228

  • 58

    JhelumPZandeeSRyanFZarrukJGMichalkeBVenkataramaniVet al. Ferroptosis induces detrimental effects in chronic EAE and its implications for progressive MS. Acta Neuropathol Commun. (2023) 11:121. doi: 10.1186/s40478-023-01617-7

  • 59

    Van SanEDebruyneACVeeckmansGTyurinaYYTyurinVAZhengHet al. Ferroptosis contributes to multiple sclerosis and its pharmacological targeting suppresses experimental disease progression. Cell Death Differ. (2023) 30:2092–103. doi: 10.1038/s41418-023-01195-0

  • 60

    LotfyAAboQuellaNMWangH. Mesenchymal stromal/stem cell (MSC)-derived exosomes in clinical trials. Stem Cell Res Ther. (2023) 14:66. doi: 10.1186/s13287-023-03287-7

  • 61

    PengTChaiMChenZWuMLiXHanFet al. Exosomes from hypoxia preconditioned muscle-derived stem cells enhance cell-free corpus cavernosa angiogenesis and reproductive function recovery. Adv Healthc Mater. (2024) 13:e2401406. doi: 10.1002/adhm.202401406

  • 62

    LiJLinLYuZHeJLiYJiangJet al. IL-1β-induced mesenchymal stem cell-derived exosomes inhibit neuronal ferroptosis in intracerebral hemorrhage through the HSPA5/GPX4 axis. Brain Res. (2024) 1845:149219. doi: 10.1016/j.brainres.2024.149219

  • 63

    TangWZhaoKLiXZhouXLiaoP. Bone marrow mesenchymal stem cell-derived exosomes promote the recovery of spinal cord injury and inhibit ferroptosis by inactivating IL-17 pathway. J Mol Neurosci MN. (2024) 74:33. doi: 10.1007/s12031-024-02209-3

  • 64

    FanJHanYSunHSunSWangYGuoRet al. Mesenchymal stem cell-derived exosomal microRNA-367-3p alleviates experimental autoimmune encephalomyelitis via inhibition of microglial ferroptosis by targeting EZH2. BioMed Pharmacother Biomedecine Pharmacother. (2023) 162:114593. doi: 10.1016/j.biopha.2023.114593

  • 65

    ZhangYXieJ. Ferroptosis-related exosomal non-coding RNAs: promising targets in pathogenesis and treatment of non-malignant diseases. Front Cell Dev Biol. (2024) 12:1344060. doi: 10.3389/fcell.2024.1344060

  • 66

    LiXZhangXLiuYZhouYGaoWWangZet al. Exosomes derived from mesenchyml stem cells ameliorate oxygen-glucose deprivation/reoxygenation-induced neuronal injury via transferring MicroRNA-194 and targeting Bach1. Tissue Cell. (2021) 73:101651. doi: 10.1016/j.tice.2021.101651

  • 67

    LiuMWLiHXiongGFZhangBRZhangQJGaoSJet al. Mesenchymal stem cell exosomes therapy for the treatment of traumatic brain injury: mechanism, progress, challenges and prospects. J Transl Med. (2025) 23:427. doi: 10.1186/s12967-025-06445-y

  • 68

    ShaoCChenYYangTZhaoHLiD. Mesenchymal stem cell derived exosomes suppress neuronal cell ferroptosis via lncGm36569/miR-5627-5p/FSP1 axis in acute spinal cord injury. Stem Cell Rev Rep. (2022) 18:1127–42. doi: 10.1007/s12015-022-10327-x

  • 69

    YiXTangX. Exosomes from miR-19b-3p-modified ADSCs inhibit ferroptosis in intracerebral hemorrhage mice. Front Cell Dev Biol. (2021) 9:661317. doi: 10.3389/fcell.2021.661317

  • 70

    ZhangLLinYBaiWSunLTianM. Human umbilical cord mesenchymal stem cell-derived exosome suppresses programmed cell death in traumatic brain injury via PINK1/Parkin-mediated mitophagy. CNS Neurosci Ther. (2023) 29:2236–58. doi: 10.1111/cns.14159

  • 71

    ZhangLBaiWPengYLinYTianM. Human umbilical cord mesenchymal stem cell-derived exosomes provide neuroprotection in traumatic brain injury through the lncRNA TUBB6/Nrf2 pathway. Brain Res. (2024) 1824:148689. doi: 10.1016/j.brainres.2023.148689

  • 72

    FanJHanYSunHSunSWangYGuoRet al. Mesenchymal stem cell-derived exosomal microRNA-367–3p alleviates experimental autoimmune encephalomyelitis via inhibition of microglial ferroptosis by targeting EZH2. BioMed Pharmacother. (2023) 162:114593. doi: 10.1016/j.biopha.2023.114593

  • 73

    WuSChenZWuYShiQYangEZhangBet al. ADSC-Exos enhance functional recovery after spinal cord injury by inhibiting ferroptosis and promoting the survival and function of endothelial cells through the NRF2/SLC7A11/GPX4 pathway. BioMed Pharmacother. (2024) 172:116225. doi: 10.1016/j.biopha.2024.116225

  • 74

    WangYLiuZLiLZhangZZhangKChuMet al. Anti-ferroptosis exosomes engineered for targeting M2 microglia to improve neurological function in ischemic stroke. J Nanobiotechnology. (2024) 22:291. doi: 10.1186/s12951-024-02560-y

  • 75

    XieKMoYYueEShiNLiuK. Exosomes derived from M2-type microglia ameliorate oxygen-glucose deprivation/reoxygenation-induced HT22 cell injury by regulating miR-124-3p/NCOA4-mediated ferroptosis. Heliyon. (2023) 9:e17592. doi: 10.1016/j.heliyon.2023.e17592

  • 76

    LiJChenQGuH. M2 microglia-derived exosomes reduce neuronal ferroptosis via FUNDC1-mediated mitophagy by activating AMPK/ULK1 signaling. Sci Rep. (2025) 15:17955. doi: 10.1038/s41598-025-03091-8

  • 77

    LiYJiangJLiJLiuSWangCYuZet al. Exosome-derived CDC42 from hypoxia-pretreated neural stem cells inhibits ACSL4-related ferroptosis to alleviate vascular injury in parkinson’s disease mice models. J Neurochem. (2025) 169:e70027. doi: 10.1111/jnc.70027

  • 78

    ZuoJCLiangJHuNYaoBZhangQJZengXLet al. Hypoxia preconditioned MSC exosomes attenuate high-altitude cerebral edema via the miR-125a-5p/RTEF-1 axis to protect vascular endothelial cells. Bioact Mater. (2025) 52:541–63. doi: 10.1016/j.bioactmat.2025.06.018

  • 79

    LiLWangHZhangJChenXZhangZLiQ. Effect of endothelial progenitor cell-derived extracellular vesicles on endothelial cell ferroptosis and atherosclerotic vascular endothelial injury. Cell Death Discov. (2021) 7:235. doi: 10.1038/s41420-021-00610-0

  • 80

    HoPTBClarkIMLeLTT. MicroRNA-based diagnosis and therapy. Int J Mol Sci. (2022) 23:7167. doi: 10.3390/ijms23137167

  • 81

    SongYLiZHeTQuMJiangLLiWet al. M2 microglia-derived exosomes protect the mouse brain from ischemia-reperfusion injury via exosomal miR-124. Theranostics. (2019) 9:2910–23. doi: 10.7150/thno.30879

  • 82

    ChenJHongJHHuangYLiuSYinJDengPet al. EZH2 mediated metabolic rewiring promotes tumor growth independently of histone methyltransferase activity in ovarian cancer. Mol Cancer. (2023) 22:85. doi: 10.1186/s12943-023-01786-y

  • 83

    HuangMChengSLiZChenJWangCLiJet al. Preconditioning Exercise Inhibits Neuron Ferroptosis and Ameliorates Brain Ischemia Damage by Skeletal Muscle-Derived Exosomes via Regulating miR-484/ACSL4 Axis. Antioxid Redox Signal. (2024) 41:769–92. doi: 10.1089/ars.2023.0492

  • 84

    LemaireQRaffo-RomeroAArabTVan CampCDragoFForteSet al. Isolation of microglia-derived extracellular vesicles: towards miRNA signatures and neuroprotection. J Nanobiotechnology. (2019) 17:119. doi: 10.1186/s12951-019-0551-6

  • 85

    CeccarelliLGiacomelliCMarchettiLMartiniC. Microglia extracellular vesicles: focus on molecular composition and biological function. Biochem Soc Trans. (2021) 49:1779–90. doi: 10.1042/BST20210202

  • 86

    GaoSJiaSBaiLLiDMengC. Transcriptome analysis unveils that exosomes derived from M1-polarized microglia induce ferroptosis of neuronal cells. Cells. (2022) 11:3956. doi: 10.3390/cells11243956

  • 87

    LiuZZengXBianWZhangYLiJChenXet al. Exosomes from muscle-derived stem cells repair peripheral nerve injury by inhibiting ferroptosis via the keap1-nrf2-ho-1 axis. J Cell Biochem. (2024) 125:e30614. doi: 10.1002/jcb.30614

  • 88

    GaoXHuWQianDBaiXHeHLiLet al. The mechanisms of ferroptosis under hypoxia. Cell Mol Neurobiol. (2023) 43:3329–41. doi: 10.1007/s10571-023-01388-8

  • 89

    LiYXuBRenXWangLXuYZhaoYet al. Inhibition of CISD2 promotes ferroptosis through ferritinophagy-mediated ferritin turnover and regulation of p62–Keap1–NRF2 pathway. Cell Mol Biol Lett. (2022) 27:81. doi: 10.1186/s11658-022-00383-z

  • 90

    LiuJHuangJZhangZZhangRSunQZhangZet al. Mesenchymal stem cell-derived exosomes ameliorate delayed neurocognitive recovery in aged mice by inhibiting hippocampus ferroptosis via activating SIRT1/nrf2/HO-1 signaling pathway. Oxid Med Cell Longev. (2022) 2022:3593294. doi: 10.1155/2022/3593294

  • 91

    ZhangYBiJHuangJTangYDuSLiP. Exosome: A review of its classification, isolation techniques, storage, diagnostic and targeted therapy applications. Int J Nanomedicine. (2020) 15:6917–34. doi: 10.2147/IJN.S264498

  • 92

    Kimiz-GebologluIOncelSS. Exosomes: Large-scale production, isolation, drug loading efficiency, and biodistribution and uptake. J Controlled Release. (2022) 347:533–43. doi: 10.1016/j.jconrel.2022.05.027

  • 93

    ImaiTTakahashiYNishikawaMKatoKMorishitaMYamashitaTet al. Macrophage-dependent clearance of systemically administered B16BL6-derived exosomes from the blood circulation in mice. J Extracell Vesicles. (2015) 4:26238. doi: 10.3402/jev.v4.26238

  • 94

    LiQWangHPengHHuyanTCacalanoNA. Exosomes: versatile nano mediators of immune regulation. Cancers. (2019) 11:1557. doi: 10.3390/cancers11101557

  • 95

    KimSKimYKKimSChoiY-SLeeIJooHet al. Dual-mode action of scalable, high-quality engineered stem cell-derived SIRPα-extracellular vesicles for treating acute liver failure. Nat Commun. (2025) 16:1903. doi: 10.1038/s41467-025-57133-w

  • 96

    CreedenJFSevierJZhangJTLapitskyYBrunicardiFCJinGet al. Smart exosomes enhance PDAC targeted therapy. J Controlled Release. (2024) 368:413–29. doi: 10.1016/j.jconrel.2024.02.037

  • 97

    Tejeda-MoraHLeonLGDemmersJBaanCCReindersMEJBleckBet al. Proteomic analysis of mesenchymal stromal cell-derived extracellular vesicles and reconstructed membrane particles. Int J Mol Sci. (2021) 22:12935. doi: 10.3390/ijms222312935

  • 98

    ChenXWangXHeMLiJZhaoYZhangQet al. Mesenchymal stem cell-derived extracellular vesicles embedded in a self-adaptive multifunctional hydrogel for rapid healing of infected wounds. Adv Healthc Mater. (2025) 14:2500980. doi: 10.1002/adhm.202500980

  • 99

    HashemiAEzatiMNasrMPZumbergIProvaznikV. Extracellular vesicles and hydrogels: an innovative approach to tissue regeneration. ACS Omega. (2024) 9:6184–218. doi: 10.1021/acsomega.3c08280

  • 100

    ZhangFZhangHWangSGaoMDuKChenXet al. A dynamically phase-adaptive regulating hydrogel promotes ultrafast anti-fibrotic wound healing. Nat Commun. (2025) 16:3738. doi: 10.1038/s41467-025-58987-w

  • 101

    HeidarzadehMGürsoy-ÖzdemirYKayaMEslami AbrizAZarebkohanARahbarghaziRet al. Exosomal delivery of therapeutic modulators through the blood–brain barrier; promise and pitfalls. Cell Biosci. (2021) 11:142. doi: 10.1186/s13578-021-00650-0

  • 102

    YuYLiWMaoLPengWLongDLiDet al. Genetically engineered exosomes display RVG peptide and selectively enrich a neprilysin variant: a potential formulation for the treatment of Alzheimer’s disease. J Drug Target. (2021) 29:1128–38. doi: 10.1080/1061186X.2021.1929257

  • 103

    TomatisFRosaSSimõesSBarãoMJesusCNovoJet al. Engineering extracellular vesicles to transiently permeabilize the blood–brain barrier. J Nanobiotechnology. (2024) 22:747. doi: 10.1186/s12951-024-03019-w

  • 104

    BaiLLiuYGuoKZhangKLiuQWangPet al. Ultrasound facilitates naturally equipped exosomes derived from macrophages and blood serum for orthotopic glioma treatment. ACS Appl Mater Interfaces. (2019) 11:14576–87. doi: 10.1021/acsami.9b00893

  • 105

    PanditRChenLGötzJ. The blood-brain barrier: Physiology and strategies for drug delivery. Adv Drug Delivery Rev. (2020) 165-166:1–14. doi: 10.1016/j.addr.2019.11.009

  • 106

    XuMFengTLiuBQiuFXuYZhaoYet al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics. (2021) 11:8926–44. doi: 10.7150/thno.62330

  • 107

    JiangCHopfnerFBergDHuMTPilottoABorroniBet al. Validation of α-synuclein in L1CAM-immunocaptured exosomes as a biomarker for the stratification of parkinsonian syndromes. Mov Disord Off J Mov Disord Soc. (2021) 36:2663–9. doi: 10.1002/mds.28591

  • 108

    ZhangJJiCZhangHShiHMaoFQianHet al. Engineered neutrophil-derived exosome-like vesicles for targeted cancer therapy. Sci Adv. (2022) 8:eabj8207. doi: 10.1126/sciadv.abj8207

  • 109

    GuoLHuangZHuangLLiangJWangPZhaoLet al. Surface-modified engineered exosomes attenuated cerebral ischemia/reperfusion injury by targeting the delivery of quercetin towards impaired neurons. J Nanobiotechnology. (2021) 19:141. doi: 10.1186/s12951-021-00879-4

  • 110

    WangHLiuXChenYLiZZhaoLZhangQet al. The regulatory role of miR-21 in ferroptosis by targeting FTH1 and the contribution of microglia-derived miR-21 in exosomes to arsenic-induced neuronal ferroptosis. J Hazard Mater. (2024) 478:135580. doi: 10.1016/j.jhazmat.2024.135580

  • 111

    GuoSWangZShiRHuangPFangYChenSet al. Engineered extracellular vesicles for targeted FGF20 delivery enhance neuroplasticity and functional recovery in ischemic stroke. J Controlled Release. (2025) 386:114080. doi: 10.1016/j.jconrel.2025.114080

  • 112

    Kawai-HaradaYNimmagaddaVHaradaM. Scalable isolation of surface-engineered extracellular vesicles and separation of free proteins via tangential flow filtration and size exclusion chromatography (TFF-SEC). BMC Methods. (2024) 1:9. doi: 10.1186/s44330-024-00009-0

  • 113

    ChenJZhengMXiaoQWangHChiCLinTet al. Recent advances in microfluidic-based extracellular vesicle analysis. Micromachines. (2024) 15:630. doi: 10.3390/mi15050630

  • 114

    LiMSoderRAbhyankarSHomeTPathakHShenXet al. Large-scale manufacturing of immunosuppressive extracellular vesicles for human clinical trials. Cytotherapy. (2025) 27:S146532492500742X. doi: 10.1016/j.jcyt.2025.06.003

  • 115

    NairABuJRawdingPADoSCLiHHongS. Cytochalasin B treatment and osmotic pressure enhance the production of extracellular vesicles (EVs) with improved drug loading capacity. Nanomaterials. (2021) 12:3. doi: 10.3390/nano12010003

  • 116

    YanWSongLWangHYangWHuLYangY. Extracellular vesicles carrying miRNA-181b-5p affects the Malignant progression of acute lymphoblastic leukemia. J Transl Med. (2021) 19:511. doi: 10.1186/s12967-021-03174-w

  • 117

    GhaziBHarmakZRghiouiMKoneASEl GhanmiABadouA. Decoding the secret of extracellular vesicles in the immune tumor microenvironment of the glioblastoma: on the border of kingdoms. Front Immunol. (2024) 15:1423232. doi: 10.3389/fimmu.2024.1423232

  • 118

    TavasolianFHosseiniAZRashidiMSoudiSAbdollahiEMomtazi-BorojeniAAet al. The impact of immune cell-derived exosomes on immune response initiation and immune system function. Curr Pharm Des. (2021) 27:197–205. doi: 10.2174/1381612826666201207221819

  • 119

    Escamilla-RiveraVSolorio-RodríguezAUribe-RamírezMLozanoOLucasSChagolla-LópezAet al. Plasma protein adsorption on Fe3O4-PEG nanoparticles activates the complement system and induces an inflammatory response. Int J Nanomedicine. (2019) 14:2055–67. doi: 10.2147/IJN.S192214

  • 120

    ThongsinNWattanapanitchM. CRISPR/cas9 ribonucleoprotein complex-mediated efficient B2M knockout in human induced pluripotent stem cells (iPSCs). In: NagyATurksenK, editors. Induced pluripotent stem (iPS) cells, vol. 2454. New York, NY: Springer US (2021). p. 607–24. Methods in Molecular Biology. doi: 10.1007/7651_2021_352

  • 121

    ThongsinNWattanapanitchM. Generation of B2M bi-allelic knockout human induced pluripotent stem cells (MUSIi001-A-1) using a CRISPR/Cas9 system. Stem Cell Res. (2021) 56:102551. doi: 10.1016/j.scr.2021.102551

  • 122

    Abdel-MalekKvon Eisenhart-RotheFStiegmannSGottmannIDopplerSASchneiderSet al. Generation of two B2M knockout induced pluripotent stem cell lines (DHMi005-A-8 and DHMi005-A-9) using CRISPR/Cas9 technology. Stem Cell Res. (2025) 87:103785. doi: 10.1016/j.scr.2025.103785

  • 123

    ChimientiRBaccegaTTorchioSManentiFPellegriniSCospitoAet al. Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-I–/– iPSCs for β cell replacement. Cell Rep. (2022) 40:111423. doi: 10.1016/j.celrep.2022.111423

  • 124

    VisanKSLobbRJHamSFalconerRScottAJohnsonEet al. Comparative analysis of tangential flow filtration and ultracentrifugation, both combined with subsequent size exclusion chromatography, for the isolation of small extracellular vesicles. J Extracell Vesicles. (2022) 11:12266. doi: 10.1002/jev2.12266

  • 125

    ChouCYChiangPCLiCCChangJWLuPHHsuWFet al. Improving the purity of extracellular vesicles by removal of lipoproteins from size exclusion chromatography- and ultracentrifugation-processed samples using glycosaminoglycan-functionalized magnetic beads. ACS Appl Mater Interfaces. (2024) 16:44386–98. doi: 10.1021/acsami.4c03869

  • 126

    PanwarDShrivastavaDKumarAGuptaLKKumarNSSChintaguntaAD. Efficient strategy to isolate exosomes using anti-CD63 antibodies conjugated to gold nanoparticles. AMB Express. (2023) 13:90. doi: 10.1186/s13568-023-01592-1

  • 127

    ChinnappanRRamadanQZourobM. An integrated lab-on-a-chip platform for pre-concentration and detection of colorectal cancer exosomes using anti-CD63 aptamer as a recognition element. Biosens Bioelectron. (2023) 220:114856. doi: 10.1016/j.bios.2022.114856

  • 128

    RouxQBoiyRDe VuystFTkachMPinheiroCDe GeyterSet al. Depletion of soluble cytokines unlocks the immunomodulatory bioactivity of extracellular vesicles. J Extracell Vesicles. (2023) 12:12339. doi: 10.1002/jev2.12339

  • 129

    WhitleyJACaiH. Engineering extracellular vesicles to deliver CRISPR ribonucleoprotein for gene editing. J Extracell Vesicles. (2023) 12:12343. doi: 10.1002/jev2.12343

Summary

Keywords

ferroptosis, exosomes, neurodegeneration, blood–brain barrier, oxidative stress

Citation

Bao X, Chen L, Yu H, Xie Y, Luo L, Luo L, Wang H, Chen R, Cheng Y, Sun D and Zhang C (2025) Exosome-based modulation of ferroptosis in neurological disorders: mechanisms, therapeutic potential, and translational challenges. Front. Immunol. 16:1677808. doi: 10.3389/fimmu.2025.1677808

Received

01 August 2025

Accepted

06 October 2025

Published

20 October 2025

Volume

16 - 2025

Edited by

Matheus Mattos, KU Leuven, Belgium

Reviewed by

Xiaocang Cao, Tianjin Medical University General Hospital, China

Menderes Yusuf Terzi, Mustafa Kemal University, Türkiye

Updates

Copyright

© 2025 Bao, Chen, Yu, Xie, Luo, Luo, Wang, Chen, Cheng, Sun and Zhang.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Da Sun, ; Chunwu Zhang,

†These authors have contributed equally to this work

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Share on WeChat

Scan with WeChat to share this article

Article metrics